… Collectively, our results revealed variable efficacy of pyrotinib in NSCLC patients with
different HER2 mutations and warrant further validation in larger randomized clinical trials. …

… patients with HER2 amplification or mutations who were … pyrotinib in other HER2-positive
solid tumors. This research explored the efficacy and safety of pyrotinib in the treatment of HER2…

… patients with HER2‑positive breast cancer had PIK3CA mutations, … analyses on pyrotinib in
patients with advanced HER2‑… the safety and efficacy of pyrotinib in neoadjuvant therapy for …

… HER2-positive MBC who were treated with pyrotinib, this study aimed to evaluate the effects
on PFS of the pyrotinib … In addition to individual mutations, this study evaluated the overall …

… of pyrotinib in advanced NSCLC patients with HER2 mutations. Inetetamab is a recombinant
humanized anti-HER2 … combined with pyrotinib could show manageable safety and more …

… , 11 patients with her2 mutated advanced NSCLC were … pyrotinib as the first line therapy
and the median previous anti-cancer regimen was 2. 9 patients had the details variants of HER2 …

… Citation14 Multiple clinical studies have confirmed the promising efficacy of pyrotinib in breast
cancer, so this study investigated the safety and efficacy of pyrotinib in HER2-positive non-…

… improved the prognosis of patients with HER2-positive breast cancer. … HER2 breast cancer,
namely, lapatinib, neratinib and pyrotinib, and systematically reviews the mechanism, safety, …

… anti-HER2 therapeutic agents. In this meta-analysis of heavily pretreated patients with HER2
mutations, anti-HER2 … In addition, pyrotinib has shown good efficacy and a tolerable safety …

… : n = 60) which evaluated the efficacy and safety of pyrotinib in HER2-mutant advanced lung
… treatment of pyrotinib in patients with HER2 mutation. We found that TP53 mutations could …